Processing Magazine

US District Court Rules in Lilly''s Favor

November 16, 2010

According to PRNewswire, Eli Lilly and Company announced that the trial on the validity of the compound patent for Alimta® (pemetrexed for injection) before the U.S. District Court for the District of Delaware ended recently with a ruling from the court that judgment would be entered in Lilly''s favor, thereby upholding the patent''s validity. The decision came in the case of Eli Lilly and Company et al v. Teva Parenteral Medicines Inc., et al. The patent provides protection for Alimta until July of 2016.